Purpose: The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.
The chemokine receptors CCR5 and CXCR4 are the two major coreceptors for HIV entry. Numerous efforts have been made to develop a new class of anti-HIV agents that target these coreceptors as an ...
Idvynso is a new once-daily, two-drug oral regimen for adults with HIV-1 who are virologically suppressed and have no history of treatment failure.
Merck’s Idvynso, a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir gets US FDA approval for the treatment of HIV-1 infection: Rahway, New Jersey ...
Morning Overview on MSN
FDA approves Merck’s Idvynso combo pill for HIV treatment
The U.S. Food and Drug Administration on April 21, 2026, approved Merck’s Idvynso, a once-daily combination pill for HIV ...
Idvynso uniquely offers a two-drug, tenofovir-free, non-INSTI single-tablet regimen intended for switch in stable, suppressed ...
MedPage Today on MSN
FDA Approves New Standalone Combo Pill for HIV
Islatravir-doravirine matched alternate regimens in two phase III trials ...
FDA approves doravirine/islatravir, a once-daily, 2-drug, single-tablet HIV regimen showing noninferior efficacy to standard ...
INSTI, tenofovir-free single-tablet maintenance option for virologically suppressed adults, expanding choices beyond ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results